scholarly journals The cervicovaginal mucus barrier to HIV-1 is diminished in bacterial vaginosis

2020 ◽  
Vol 16 (1) ◽  
pp. e1008236 ◽  
Author(s):  
Thuy Hoang ◽  
Emily Toler ◽  
Kevin DeLong ◽  
Nomfuneko A. Mafunda ◽  
Seth M. Bloom ◽  
...  
2020 ◽  
Vol 21 (21) ◽  
pp. 8266
Author(s):  
Guillaume Lacroix ◽  
Valérie Gouyer ◽  
Frédéric Gottrand ◽  
Jean-Luc Desseyn

Preterm births are a global health priority that affects 15 million babies every year worldwide. There are no effective prognostic and therapeutic strategies relating to preterm delivery, but uterine infections appear to be a major cause. The vaginal epithelium is covered by the cervicovaginal mucus, which is essential to health because of its direct involvement in reproduction and functions as a selective barrier by sheltering the beneficial lactobacilli while helping to clear pathogens. During pregnancy, the cervical canal is sealed with a cervical mucus plug that prevents the vaginal flora from ascending toward the uterine compartment, which protects the fetus from pathogens. Abnormalities of the cervical mucus plug and bacterial vaginosis are associated with a higher risk of preterm delivery. This review addresses the current understanding of the cervicovaginal mucus and the cervical mucus plug and their interactions with the microbial communities in both the physiological state and bacterial vaginosis, with a focus on gel-forming mucins. We also review the current state of knowledge of gel-forming mucins contained in mouse cervicovaginal mucus and the mouse models used to study bacterial vaginosis.


mBio ◽  
2015 ◽  
Vol 6 (5) ◽  
Author(s):  
Kenetta L. Nunn ◽  
Ying-Ying Wang ◽  
Dimple Harit ◽  
Michael S. Humphrys ◽  
Bing Ma ◽  
...  

ABSTRACTCervicovaginal mucus (CVM) can provide a barrier that precludes HIV and other sexually transmitted virions from reaching target cells in the vaginal epithelium, thereby preventing or reducing infections. However, the barrier properties of CVM differ from woman to woman, and the causes of these variations are not yet well understood. Using high-resolution particle tracking of fluorescent HIV-1 pseudoviruses, we found that neither pH nor Nugent scores nor total lactic acid levels correlated significantly with virus trapping in unmodified CVM from diverse donors. Surprisingly, HIV-1 was generally trapped in CVM with relatively high concentrations ofd-lactic acid and aLactobacillus crispatus-dominant microbiota. In contrast, a substantial fraction of HIV-1 virions diffused rapidly through CVM with low concentrations ofd-lactic acid that had aLactobacillus iners-dominant microbiota or significant amounts ofGardnerella vaginalis, a bacterium associated with bacterial vaginosis. Our results demonstrate that the vaginal microbiota, including specific species ofLactobacillus, can alter the diffusional barrier properties of CVM against HIV and likely other sexually transmitted viruses and that these microbiota-associated changes may account in part for the elevated risks of HIV acquisition linked to bacterial vaginosis or intermediate vaginal microbiota.IMPORTANCEVariations in the vaginal microbiota, especially shifts away fromLactobacillus-dominant microbiota, are associated with differential risks of acquiring HIV or other sexually transmitted infections. However, emerging evidence suggests thatLactobacillus inersfrequently colonizes women with recurring bacterial vaginosis, raising the possibility thatL. inersmay not be as protective as otherLactobacillusspecies. Our study was designed to improve understanding of how the cervicovaginal mucus barrier against HIV may vary between women along with the vaginal microbiota and led to the finding that the vaginal microbiota, including specific species ofLactobacillus, can directly alter the diffusional barrier properties of cervicovaginal mucus. This work advances our understanding of the complex barrier properties of mucus and highlights the differential protective ability of different species ofLactobacillus, withLactobacillus crispatusand possibly other species playing a key role in protection against HIV and other sexually transmitted infections. These findings could lead to the development of novel strategies to protect women against HIV.


2009 ◽  
Vol 49 (6) ◽  
pp. 991-992 ◽  
Author(s):  
Carla Moreira ◽  
Kartik K. Venkatesh ◽  
Allison DeLong ◽  
Tao Liu ◽  
Jaclyn Kurpewski ◽  
...  

2008 ◽  
Vol 48 (2) ◽  
pp. 203-210 ◽  
Author(s):  
Janneke H H M van de Wijgert ◽  
Charles S Morrison ◽  
Peter G A Cornelisse ◽  
Marshall Munjoma ◽  
Jeanne Moncada ◽  
...  

The Lancet ◽  
1997 ◽  
Vol 350 (9086) ◽  
pp. 1251-1252 ◽  
Author(s):  
S Ledru ◽  
N Méd ◽  
E Ledru ◽  
AJ Bazie ◽  
JP Chiron

2011 ◽  
Vol 12 (2) ◽  
pp. 22-24
Author(s):  
Robert D Kirkcaldy ◽  
Jennifer Mika ◽  
Lori M Newman ◽  
Judite Langa ◽  
Linhui Tian ◽  
...  

Objectives. We investigated whether abnormal vaginal flora, including bacterial vaginosis (BV), are associated with detection of cervical HIV-1 RNA among HIV-infected women in Mozambique. Methods. We obtained clinical data and vaginal specimens from HIV-infected women registering for their first visit at one of two HIV care clinics in Mozambique. We compared women with detectable cervical HIV viral load (≥40 copies/ml) with women with undetectable cervical HIV. Results. We enrolled 106 women. Women with abnormal vaginal flora (intermediate Nugent scores, 4 - 6) were more likely to have detectable cervical HIV RNA then women with normal vaginal flora (adjusted odds ratio 7.2 (95% confidence interval 1.8 - 29.1), adjusted for CD4 count). Women with BV had a non-significantly higher likelihood of detectable cervical HIV than women with normal flora. Conclusions. Abnormal vaginal flora were significantly associated with cervical HIV expression. Further research is needed to confirm this relationship.


2014 ◽  
Vol 41 (2) ◽  
pp. 123-128 ◽  
Author(s):  
Jennifer E. Balkus ◽  
Barbra A. Richardson ◽  
Lorna K. Rabe ◽  
Taha E. Taha ◽  
Nyaradzo Mgodi ◽  
...  

2009 ◽  
Vol 2009 ◽  
pp. 1-6 ◽  
Author(s):  
Caroline Mitchell ◽  
Carla Moreira ◽  
David Fredricks ◽  
Kathleen Paul ◽  
Angela M. Caliendo ◽  
...  

Background. Fastidious bacteria have been associated with bacterial vaginosis (BV) using PCR methods. We assessed the prevalence of these bacteria in HIV-1 infected women and their relationship with vaginal pH and shedding of HIV-1 RNA.Methods. 64 cervicovaginal lavage (CVL) samples were collected from 51 women. Vaginal microbiota were characterized using 8 bacterium-specific quantitative PCR assays.Results. Women with the fastidious bacteria Bacterial Vaginosis Associated Bacterium (BVAB) 1, 2, and 3 showed a trend to increased HIV-1 shedding (OR 2.59–3.07,P=.14–.17). Absence ofLactobacillus crispatus(P<.005) and presence of BVAB2 (P<.001) were associated with elevated vaginal pH. BVAB1, 2, and 3 were highly specific indicators of BV in HIV-infected women, with specificities of 89%–93%.Conclusions. Fastidious bacteria (BVAB 1, 2, and 3) remain specific indicators of BV in HIV-infected women, and BVAB2 may contribute to the elevated vaginal pH that is a hallmark of this syndrome.


2002 ◽  
Vol 13 (11) ◽  
pp. 755-760 ◽  
Author(s):  
R Wiggins ◽  
M R Millar ◽  
P W Soothill ◽  
S J Hicks ◽  
A P Corfield

Enzymes produced in bacterial vaginosis (BV) have been proposed as possible mediators of pre-term birth. Most studies have concentrated on mid-trimester measurements of enzyme activity, and utilize synthetic substrates to measure enzyme activity, which may not accurately represent mucinase activity in vivo. We have developed a novel ELISA mucinase assay using biotinylated human cervical mucin as a substrate. The assay is rapid, sensitive and can be used to screen large numbers of samples. The new assay has been used to assess vaginal mucinase activities in 92 women <14 weeks gestational age with and without BV. No differences in mucinase activity were detected between normal and BV groups while significant elevation of sialidase and other glycosidases was confirmed as reported before. This study shows that significant mucinase activity is a normal event in the mucus barrier, but does not reflect changes identified for individual enzyme activities associated with BV.


Author(s):  
Lena Al-Harthi ◽  
Kenneth A. Roebuck ◽  
Gene G. Olinger ◽  
Alan Landay ◽  
Beverly E. Sha ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document